Literature DB >> 18624931

CXCR-4 knockdown by small interfering RNA inhibits cell proliferation and invasion of oral squamous cell carcinoma cells.

Ji-Soo Hong1, Hyun-Kyung Pai, Kyoung-Ok Hong, Mi-Ae Kim, Ji-Hong Kim, Jae-Il Lee, Sam-Pyo Hong, Seong-Doo Hong.   

Abstract

BACKGROUND: Oral squamous cell carcinomas (OSCCs) are characterized by a high degree of local invasion and a high rate of metastases to cervical lymph nodes. Downregulation of CXCR-4 by siRNA inhibits invasion and growth of breast and colon cancer cells. However, there have been no reports on the downregulation of CXCR-4 by small interfering RNA (siRNA) in oral cancer cells.
METHODS: We generated two stable CXCR-4-knockdown clones (KBsi and KOSCC-25Bsi) from the KB and KOSCC-25B OSCC cell lines by lentiviral delivery. In vitro invasion and cell proliferation assays were used to investigate the effect of CXCR-4 downregulation on cell proliferation and invasiveness in KBsi and KOSCC-25Bsi. Immunohistochemistry was performed to evaluate the correlation between CXCR-4 expression and proliferation in 26 OSCC tissue samples.
RESULTS: CXCR4-knockdown OSCC cells showed reduced invasiveness. The invasiveness of KBsi decreased to 29.5% of the vector-infected controls, and KOSCC-25Bsi decreased to 38.1% of the control vector-infected cells (P < 0.05). The CXCR4-knockdown OSCC cells grew significantly slower than the vector-infected control cells. KBsi and KOSCC-25Bsi cells proliferated at 69.5% and 71.7%, respectively, of the rate of control vector-infected cells (P < 0.05). CXCR-4-positive group had significantly higher PCNA labeling index than CXCR-4-negative group in OSCC tissue samples.
CONCLUSION: These results suggest that the downregulation of CXCR-4 induces anti-proliferative and anti-invasive effects in OSCC and that CXCR-4 might be a useful target molecule for the treatment of OSCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18624931     DOI: 10.1111/j.1600-0714.2008.00671.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  15 in total

1.  CXCL12-CXCR4/CXCR7 axis contributes to cell motilities of oral squamous cell carcinoma.

Authors:  Na Chen; Xiao Jiang; Juan Wang; Tong Wu; Bin Cheng; Juan Xia
Journal:  Tumour Biol       Date:  2015-08-02

2.  CXCR4, but not CXCR7, discriminates metastatic behavior in non-small cell lung cancer cells.

Authors:  Young H Choi; Marie D Burdick; Brett A Strieter; Borna Mehrad; Robert M Strieter
Journal:  Mol Cancer Res       Date:  2013-09-11       Impact factor: 5.852

Review 3.  Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Authors:  Won-Tak Choi; Yilei Yang; Yan Xu; Jing An
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

4.  CXCR4 and PD-1 Expression in Head and Neck Cancer with Perineural Spread.

Authors:  Catherine M Barnett; Ryan S Sommerville; Charles Lin; Gishan Ratnayake; Brett Hughes; Touraj Taheri
Journal:  J Neurol Surg B Skull Base       Date:  2018-06-14

5.  Expression of the CXCL12/CXCR4 chemokine axis predicts regional control in head and neck squamous cell carcinoma.

Authors:  Xavier León; Santiago Diez; Jacinto García; Joan Lop; Anna Sumarroca; Miquel Quer; Mercedes Camacho
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-06-21       Impact factor: 2.503

6.  RNAi targeting CXCR4 inhibits tumor growth through inducing cell cycle arrest and apoptosis.

Authors:  Tao Yu; Yingying Wu; Yi Huang; Chaoran Yan; Ying Liu; Zongsheng Wang; Xiaoyi Wang; Yuming Wen; Changmei Wang; Longjiang Li
Journal:  Mol Ther       Date:  2011-11-22       Impact factor: 11.454

7.  Inhibition of chemokine receptor expression on uveal melanomas by CXCR4 siRNA and its effect on uveal melanoma liver metastases.

Authors:  Haochuan Li; Wanhua Yang; Peter W Chen; Hassan Alizadeh; Jerry Y Niederkorn
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-06-24       Impact factor: 4.799

8.  CXC receptor-4 mRNA silencing abrogates CXCL12-induced migration of colorectal cancer cells.

Authors:  Claudia Rubie; Vilma O Frick; Pirus Ghadjar; Mathias Wagner; Christoph Justinger; Sabrina K Faust; Benjamin Vicinus; Stefan Gräber; Otto Kollmar; Martin K Schilling
Journal:  J Transl Med       Date:  2011-02-24       Impact factor: 5.531

9.  Expressions of CXCL12/CXCR4 in oral premalignant and malignant lesions.

Authors:  Juan Xia; Na Chen; Yun Hong; Xiaobing Chen; Xiaoan Tao; Bin Cheng; Yulei Huang
Journal:  Mediators Inflamm       Date:  2012-01-29       Impact factor: 4.711

10.  Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells.

Authors:  Kyoung-Ok Hong; Ji-Hong Kim; Ji-Soo Hong; Hye-Jung Yoon; Jae-Il Lee; Sam-Pyo Hong; Seong-Doo Hong
Journal:  J Exp Clin Cancer Res       Date:  2009-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.